Allogene Therapeutics (ALLO) Soars 8.4%: Is Further Upside Left in the Stock?

QGEN ALLO

Allogene Therapeutics (ALLO - Free Report) shares ended the last trading session 8.4% higher at $9.76. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6% loss over the past four weeks.

The rise in share prices is attributable to positive investor expectations on the company’s progress with its pipeline development of genetically engineered allogeneic CAR T (AlloCAR T) therapies for the treatment of cancer. In fact, earlier this month, Allogene’s first AlloCAR T solid tumor clinical candidate, ALLO-316, was granted Fast Track designation by the FDA as a potential treatment for patients with advanced or metastatic clear cell renal cell carcinoma.

This immuno-oncology company is expected to post quarterly loss of $0.59 per share in its upcoming report, which represents a year-over-year change of -136%. Revenues are expected to be $0.1 million, down 99.7% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Allogene Therapeutics, the consensus EPS estimate for the quarter has been revised 6.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ALLO going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Allogene Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Qiagen (QGEN - Free Report) , finished the last trading session 2.3% higher at $49.94. QGEN has returned -0.8% over the past month.

Qiagen's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.72. Compared to the company's year-ago EPS, this represents a change of +9.1%. Qiagen currently boasts a Zacks Rank of #3 (Hold).

Buy 5 Stocks BEFORE Election Day

Biden or Trump? Zacks is releasing a FREE Special Report, Profit from the 2024 Presidential Election (no matter who wins).

Since 1950, presidential election years have been strong for the market. This report names 5 timely stocks to ride the wave of electoral excitement.

They include a medical manufacturer that gained +11,000% in the last 15 years… a rental company absolutely crushing its sector… an energy powerhouse planning to grow its already large dividend by 25%... an aerospace and defense standout that just landed a potentially $80 billion contract… and a giant chipmaker building huge plants in the U.S. 

Don’t Wait. Download FREE >>